25 March 2026 - Apotex today announced that Health Canada has approved Clobivis (clobetasol propionate ophthalmic suspension, 0.05%), indicated for the treatment of postoperative inflammation and pain following cataract surgery.

Licensed from Formosa, Clobivis is formulated using nanoparticle technology to deliver a uniform, ophthalmic suspension.

Read Apotex press release